Orphalan announces China NMPA’s approval of its trientine tetrahydrochloride product for the treatme
Paris, France 18 January, 2024 - Orphalan SA (“Orphalan” or “the Company”), an international orphan drug development and commercialization company, today announces the approval of its trientine tetrahydrochloride product by China's National Medical Products Administration (NMPA). This product, already marketed as Cuprior® in the EU, the UK, Saudi Arabia, Switzerland, and Colombia, and as Cuvrior® in the US, represents the first trientine approved by the NMPA. It offers a new treatment option for Wilson disease in children aged five years and older and adults intolerant to penicillamine therapy.
China is home to an estimated 80,000 individuals with Wilson disease, of whom approximately half have their diagnosis confirmed, and 25,000 are receiving regular treatment. The introduction of new treatment alternatives such as Orphalan’s trientine tetrahydrochloride, particularly for patients who are intolerant to currently available therapies, presents a significant opportunity to meet the needs of a broader segment of the Wilson disease population in China. Orphalan anticipates its product to be available in the country in the coming months.
Dr Naseem Amin, Chief Executive Officer at Orphalan, said: “We are pleased with the marketing authorisation approval of our trientine tetrahydrochloride product in China, which offers a well-tolerated and effective treatment option for patients with Wilson disease. This approval is a crucial step towards providing a much-needed treatment option for the Wilson disease community in China and reaffirms our commitment to improving the experience for patients living with rare diseases worldwide.”
Yan Qin, Director of Wuhan Tongxin (Wilson disease patient group in China) added: “We were thrilled when we heard that NMPA approved Orphalan's trientine tetrahydrochloride in China. It is a significant step for those of us living with Wilson disease, representing a much-needed alternative treatment option. This approval, a result of Orphalan's patient-focused approach, offers us a chance to better manage our condition with a new, effective treatment.”
Wilson disease is a rare inherited disorder of copper transport primarily affecting the liver and brain. Early treatment with legacy agents such as D-penicillamine (DPA), trientine HCI, and zinc salts can effectively slow the progression of the disease, however these options may not be suitable for long-term care due to adverse events associated with DPA and the need for close monitoring during treatment with zinc salts and DPA.
ENDS
About Orphalan
Orphalan is an international orphan drug development and commercialization company headquartered in Paris. Founded in 2011, the Company develops and deliver innovative therapies for people living with rare and debilitating diseases. Our trientine tetrahydrochloride product has been approved for the treatment of Wilson disease and is available in more than 20 countries, branded as Cuprior® in EU, the UK, Saudi Arabia, Switzerland and Columbia, and as Cuvrior® in the United States. For more information visit www.orphalan.com and follow us on LinkedIn.
For more information, please contact:
Orphalan:
Géraldine van den Broek, Head of Corporate & BD
Tel: +33 (0)1 42 49 82 64
ICR Consilium:
Tracy Cheung, Sukaina Virji, Davide Salvi
Tel: +44 (0) 203 709 5700
- 如何利用球团的余热回收技术实现能源节约与环境保护(圣昊朗道)
- 李锦记蚝油荣获绿色产品评价,传承百年的中国味获“独家认证”
- 井藤汉方速攻系列为什么11连冠稳居销量榜首?
- Thermax与Ceres合作,在印度进行大规模固体氧化物电解(SOEC)制造,实现绿色氢气生产
- 越秀济南·百脉悦府|卓尔不凡,墅启大家风范
- 咸阳工程服务网:激发建筑行业新活力,赋能企业数字化转型!
- 引领“光明”未来——帝莱特便携晨光产品荣登央广网《品质国货》品牌直播
- Mike 曾比特首次马来西亚宣传 希望产出更多代表作
- 2024第二届全国先进计算技术创新大赛智能计算专题赛在济圆满落幕
- 上海大流士新歌《空气说》发行深情诠释对过去的浪漫告别
- 凯帝雅,一个专注于高端零食、礼品与伴手礼的品牌
- 榆林好物亮相杭州,全国年货博览会取得丰硕成果
- 中医专家紧急提醒:麻木比疼痛更危险!百年古方破解气血难题
- 南方东英美股七巨头ETF (3454.HK) 将于明日在香港交易所上市
- Medisca 的新篇章:Sanjay D. Goorachurn 被任命为首席执行官
- Mavenir to Present Go-Forward Corporate Strategy at Annual Global Analyst Event in Dallas
- 第三届中国(青岛)人力资源服务外包大会圆满收官,闪耀行业之光
- AI For 3D Generation | OPENAIGC开发者大赛企业组钻石奖
- 焕然「星」升 依视路®星趣控®2.0镜片重磅发布
- 关地暖区别于关空调,大有讲究!大金官方发布地暖关机指南
推荐
-
一个“江浙沪人家的孩子已经不卷学习了”的新闻引发议论纷纷 星标★ 来源:桌子的生活观(ID:zzdshg) 没 资讯
-
中央气象台连发四则气象灾害预警 暴雪橙色预警+冰冻橙色预警+大雾黄色预警+ 资讯
-
新增供热能力3200万平方米 新疆最大热电联产项目开工 昨天(26日),新疆最大的热电联产项目—&md 资讯
-
奥运冠军刘翔更新社交账号晒出近照 时隔473天更新动态! 2月20日凌晨2点,奥运冠军刘翔更新社交账号晒 资讯
-
男子“机闹”后航班取消,同机旅客准备集体起诉 1月4日,一男子大闹飞机致航班取消的新闻登上 资讯
-
看新东方创始人俞敏洪如何回应董宇辉新号分流的? (来源:中国证券报) 东方甄选净利润大幅下滑 资讯
-
国足13次出战亚洲杯首次小组赛0进球 北京时间1月23日消息,2023亚洲杯小组 资讯
-
透过数据看城乡居民医保“含金量” 缴费标准是否合理? 记者从国家医保局了解到,近期,全国大部分地区 资讯
-
大家一起关注新疆乌什7.1级地震救援见闻 看到热气腾腾的抓饭马上就要出锅、村里大家 资讯
-
周星驰新片《少林女足》在台湾省举办海选,吸引了不少素人和足球爱好者前来参加 周星驰新片《少林女足》在台湾省举办海选,吸 资讯